**Supplemental Table S1. Change From DB Baseline to Week 40 (Non-Flared Patients) or to Flare Week 16 (Patients Who Flared) in Secondary Endpoints**

| Change from DB baseline, mean (SD) | Patients Who Did Not Flare | Patients Who Flared |
|-----------------------------------|----------------------------|---------------------|
|                                   | Taper Arm at Week 40       | Withdrawal Arm at Week 40 | Taper Arm at Flare Week 16 | Withdrawal Arm at Flare Week 16 |
| Synovitis RAMRIS                  | 0.1 (1.3)  
  n=51                        | −0.1 (0.9)  
  n=10                        | 0.8 (1.8)  
  n=25                        | 0.1 (1.8)  
  n=7                         |
| BME RAMRIS                        | 0.0 (1.1)  
  n=52                        | 1.2 (3.5)  
  n=10                        | −0.1 (0.5)  
  n=26                        | 0.3 (0.4)  
  n=8                         |
| Composite of synovitis and BME RAMRIS | 0.1 (1.9)  
  n=51                        | 1.1 (2.9)  
  n=10                        | 0.7 (1.9)  
  n=25                        | 0.4 (1.8)  
  n=7                         |
| Tenosynovitis RAMRIS              | 0.8 (1.8)  
  n=25                        | 0.1 (1.8)  
  n=7                         |
| Inflammation RAMRIS*              | 0.1 (2.5)  
  n=39                        | 1.2 (3.2)  
  n=9                         | 0.8 (2.5)  
  n=22                        | −0.9 (1.0)  
  n=4                         |
| Erosion RAMRIS                    | 0.1 (0.5)  
  n=52                        | 0.0 (1.1)  
  n=10                        | 0.3 (1.0)  
  n=26                        | 0.1 (0.9)  
  n=8                         |
| DAS28(ESR)                        | 0.0 (0.5)  
  n=63                        | 0.2 (0.4)  
  n=11                        | 1.2 (1.0)  
  n=29                        | 0.6 (0.8)  
  n=8                         |
| CDAI                              | 0.1 (1.3)  
  n=63                        | −0.3 (0.5)  
  n=11                        | 4.5 (6.1)  
  n=29                        | 2.8 (4.2)  
  n=8                         |
| SDAI                              | 0.1 (1.4)  
  n=63                        | −0.3 (0.6)  
  n=11                        | 3.6 (6.6)  
  n=29                        | 2.7 (4.2)  
  n=8                         |
| HAQ-DI                            | −0.1 (0.3)  
  n=63                        | 0.0 (0.2)  
  n=11                        | 0.2 (0.4)  
  n=29                        | 0.1 (0.2)  
  n=7                         |
| SJC28                             | 0.0 (0.4)  
  n=63                        | −0.1 (0.3)  
  n=11                        | 0.9 (1.8)  
  n=30                        | 0.3 (0.5)  
  n=8                         |
| TJC28                             | 0.0 (0.5)  
  n=63                        | 0.0 (0.0)  
  n=11                        | 1.8 (2.6)  
  n=30                        | 1.1 (1.9)  
  n=8                         |
| ESR                               | 1.4 (7.2)  
  n=63                        | 4.7 (8.9)  
  n=11                        | 8.0 (11.0) | 7.0 (14.4) |
| PGA                               | 1.0 (5.3)  
  n=63                        | −0.6 (2.4)  
  n=11                        | 8.6 (12.5) | 7.6 (20.0) |
| PtGA                              | 0.0 (7.6)  
  n=63                        | −1.7 (4.5)  
  n=11                        | 9.4 (13.5) | 6.9 (9.3)  |
| PtGA RA pain                       | −0.5 (10.0)  
  n=63                        | −0.9 (5.1)  
  n=11                        | 8.0 (14.4) | 4.3 (6.3)  |
| RAPID-3                           | 0.0 (2.4)  
  n=63                        | 0.8 (1.6)  
  n=11                        | 2.9 (4.2)  
  n=29                        | 2.1 (3.0)  
  n=7                         |
| SF-36 PCS                          | −0.4 (5.5)  
  n=60                        | −2.1 (5.2)  
  n=11                        | −3.8 (7.4) | −2.5 (2.8) |
| SF-36 MCS                          | −0.8 (5.9)  
  n=60                        | −0.4 (6.7)  
  n=11                        | −4.0 (11.0) | 0.1 (2.6)  |

Supplementary material

Ann Rheum Dis

doi: 10.1136/annrheumdis-2020-217246
| FACIT-fatigue | n=60  | -0.4 (4.0) | n=11  | -1.5 (4.8) | n=28 | -4.5 (9.0) | n=7 | -1.7 (1.9) |

Increase in scores indicates worsening for all endpoints, except for SF-36 and FACIT-fatigue in which increase in score represents better health.

LOCF analysis.

BME, bone marrow edema; CDAI, Clinical Disease Activity Index; DAS28(ESR), 28-joint Disease Activity Score based on erythrocyte sedimentation rate; DB, double-blind; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire Disability Index; LOCF, last observation carried forward; MCS, mental component summary; PCS, physical component summary; PGA, Physician Global Assessment of disease activity; PtGA, Patient Global Assessment of disease activity; RAMRIS, Rheumatoid Arthritis Magnetic Resonance Imaging Score; SDAI, Simplified Disease Activity Index; SF-36, Short Form 36 Health Survey Questionnaire.

*Composite of synovitis, BME and tenosynovitis RAMRIS.
### Supplemental Table S2. Change From DB Baseline to Flare Week 0 in Secondary Endpoints Among Patients Who Flared

| Endpoint         | Taper Arm     | Withdrawal Arm |
|------------------|---------------|----------------|
| DAS28(ESR)       | 2.3 (1.2)     | 1.9 (1.0)      |
|                  | n=30          | n=8            |
| CDAI             | 12.3 (9.6)    | 9.4 (9.1)      |
|                  | n=30          | n=8            |
| SDAI             | 11.6 (11.2)   | 9.9 (8.3)      |
|                  | n=30          | n=8            |
| HAQ-DI           | 0.4 (0.6)     | 0.3 (0.3)      |
|                  | n=25          | n=7            |
| SJC28            | 2.3 (2.6)     | 1.9 (2.1)      |
|                  | n=30          | n=8            |
| TJC28            | 4.4 (4.6)     | 3.6 (3.8)      |
|                  | n=30          | n=8            |
| ESR              | 10.4 (12.5)   | 13.0 (11.9)    |
|                  | n=30          | n=8            |
| PGA              | 26.5 (23.3)   | 17.4 (15.4)    |
|                  | n=30          | n=8            |
| PtGA             | 29.5 (29.4)   | 21.6 (27.1)    |
|                  | n=30          | n=8            |
| PtGA RA pain     | 24.4 (31.7)   | 17.0 (19.4)    |
|                  | n=30          | n=8            |
| RAPID-3          | 6.1 (6.6)     | 3.9 (5.6)      |
|                  | n=30          | n=8            |
| SF-36 PCS        | −10.8 (10.9)  | −2.4 (10.8)    |
|                  | n=22          | n=5            |
| SF-36 MCS        | −4.1 (11.4)   | 0.4 (4.6)      |
|                  | n=22          | n=5            |
| FACIT-fatigue    | −7.4 (11.2)   | −3.6 (4.8)     |
|                  | n=28          | n=8            |

Increase in scores indicates worsening for all endpoints, except for SF-36 and FACIT-fatigue in which increase in score represents better health.

LOCF analysis.

CDAI, Clinical Disease Activity Index; DAS28(ESR), 28-joint Disease Activity Score based on erythrocyte sedimentation rate; DB, double-blind; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire Disability Index; LOCF, last observation carried forward; MCS, mental component summary; PCS, physical component summary; PGA, Physician Global Assessment of disease activity; PtGA, Patient Global Assessment of disease activity; SDAI, Simplified Disease Activity Index; SF-36, Short Form 36 Health Survey Questionnaire.